| Clinical data | |
|---|---|
| Other names | ETX2514 |
| Routes of administration | Intravenous |
| Drug class | Antibacterial,beta-lactamase inhibitor |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C8H11N3O6S |
| Molar mass | 277.25 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Durlobactam is abeta-lactamase inhibitor used in combination withsulbactam to treat susceptible strains of bacteria in the genusAcinetobacter[1] It is an analog ofavibactam.
The combination therapysulbactam/durlobactam was approved for medical use in the United States in May 2023.[1]
This systemicantibiotic-related article is astub. You can help Wikipedia byexpanding it. |